Furthermore, the findings implied that the substantial adverse outcomes of elevated GH levels at diagnosis and subsequent endocrine-metabolic (except diabetes), musculoskeletal and cardiovascular comorbidities were associated with diagnostic delay. Here, GH1 is linked to diabetes mellitus.